ICU patient information database for adults
This trial collects and studies health information from people who are critically ill and admitted to an intensive care unit. It may help doctors learn how to better care for ICU patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be admitted to an intensive care unit (ICU).
- You must be critically ill at the time of ICU admission.
- You must be 20 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study focuses on critically ill people in the intensive care unit (ICU). It aims to learn what affects outcomes and resources, which may help improve how care is planned for ICU patients.
This trial sets up a way to collect and store physiological readings (like vital-sign data) from adults in the intensive care unit. It aims to improve how doctors understand and monitor critically ill patients over time.
This study talks to adults who have been in an intensive care unit (ICU) to understand their views on life-sustaining treatments, end-of-life wishes, and when they would want less or more care. It aims to improve how doctors and families make these hard decisions together.
This major trial tests multiple treatments at once for adults admitted to the ICU. If you are an ICU patient, you may be able to join and receive one of several possible treatments aimed at improving recovery.
This study looks at how your immune system and inflammation affect your recovery in the intensive care unit. Researchers want to understand why some patients do better than others.
This study looks at how nutrition is given to adults in the intensive care unit (ICU). It aims to understand current practices and may help improve care for future patients.
Hear when a new Critical Illness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.